Clinical Trial

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 18, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.
Trial Details
NCT Number NCT07072169
Lead Sponsor Ruijin Hospital
Conditions B-cell Non-Hodgkin Lymphoma
Enrollment 56 participants
Start Date 2025-05-26
Primary Completion 2026-06 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-07-18